trending Market Intelligence /marketintelligence/en/news-insights/trending/-9tbHNI0fM1LMIwWazVwkQ2 content esgSubNav
In This List

Regenxbio receives $100M accelerated license payment from AveXis

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Regenxbio receives $100M accelerated license payment from AveXis

Regenxbio Inc. received an accelerated license payment of $100 million from AveXis Inc. under a licensing deal to develop and sell therapies for spinal muscular atrophy, a genetic disease affecting the nervous system.

The accelerated payment is due to Novartis AG's $8.7 billion acquisition of AveXis, Regenxbio said in a news release. The payment includes $60 million in annual fees and a $40 million commercial milestone fee.

Rockville, Md.-based Regenxbio remains eligible for a potential milestone fee of $80 million, as well as royalties on net sales for any product developed under the license deal, which the companies expanded in January.

Meanwhile, Novartis now holds the exclusive rights to Regenxbio's NAV technology platform for developing therapies for spinal muscular atrophy.

The disease, a leading genetic cause of infant deaths, affects the part of the nervous system that controls voluntary muscle movement.